Cg Oncology, INC 8-K filings

CG Oncology announced its second quarter 2026 financial results, highlighting significant progress in its clinical development programs and a robust cash position sufficient through 2029.

CG Oncology, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

CG Oncology announced the separation of its President & Chief Operating Officer, Ambaw Bellete, effective June 30, 2026, and the appointment of Arthur Kuan as President.

CG Oncology announced its first quarter 2026 financial results, highlighting progress towards a BLA submission for its lead candidate and a strong cash position sufficient through 2029.

CG Oncology, Inc. announced the appointment of Jim DeTore as its new Chief Financial Officer, effective April 13, 2026, with a compensation package including salary, bonus, stock options, and performance stock units.

CG Oncology, Inc. announced its financial results for the year and fourth quarter ended December 31, 2025, alongside significant progress in its bladder cancer clinical programs and a strong cash position.

CG Oncology, Inc. increased its at-the-market equity offering program by an additional $300 million, bringing the total potential raise to $550 million.

CG Oncology announced an expedited timeline for its PIVOT-006 Phase 3 trial data and reported positive early results from BOND-003 Cohort P and CORE-008 Cohort A for bladder cancer treatments.

CG Oncology, Inc. announced the appointment of Christina Rossi to its Board of Directors and the immediate resignation of Simone Song.

CG Oncology, Inc. announced the resignation of its interim principal financial and accounting officer, Robert Lapetina, and the appointment of Jim DeTore to the role, effective November 17, 2025.

CG Oncology reports Q3 2025 financial results, initiates BLA submission for cretostimogene, and maintains strong cash position.

CG Oncology presented updated corporate data highlighting cretostimogene's best-in-disease durability and safety in bladder cancer.

CG Oncology announced updated Phase 3 data for cretostimogene, demonstrating robust 24-month complete response and durability in high-risk BCG-unresponsive NMIBC patients.

CG Oncology announced its second quarter 2025 financial results, highlighted by positive clinical trial data for cretostimogene and a favorable outcome in the ANI Pharmaceuticals litigation.

CG Oncology, Inc. announced the resignation of its Chief Financial Officer, Corleen Roche, effective August 5, 2025, and the appointment of Robert Lapetina as interim principal financial and accounting officer.

CG Oncology, Inc. announced the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

CG Oncology reported its Q1 2025 financial results and highlighted promising clinical trial updates, including positive data from its BOND-003 and CORE-008 trials for bladder cancer treatment.

CG Oncology reports promising results from its BOND-003 trial for cretostimogene in bladder cancer, showing durable complete responses and high recurrence-free survival rates.

CG Oncology announces positive financial results for 2024, highlighted by a successful equity offering and promising clinical trial updates for its bladder cancer therapy, Cretostimogene.

CG Oncology announces positive Phase 3 trial results for cretostimogene in BCG-unresponsive non-muscle invasive bladder cancer, demonstrating a 75.5% complete response rate and a median duration of response exceeding 28 months.

CG Oncology updated employment agreements with its CEO, President/COO, CMO, CFO, and General Counsel/CCO on January 9, 2025, detailing severance benefits under various termination scenarios.

CG Oncology reports positive topline data from its Phase 3 BOND-003 trial, showing a 74.5% complete response rate for cretostimogene in high-risk bladder cancer patients.

CG Oncology announced its third quarter 2024 financial results, highlighting progress in its clinical trials and a strong cash position.

CG Oncology reported positive results from its CORE-001 and BOND-003 studies, highlighting the potential of cretostimogene as a bladder-sparing therapy for bladder cancer, and provided a business update.

CG Oncology reported positive final results from its Phase 2 CORE-001 trial, showing a significant complete response rate for its bladder cancer therapy, cretostimogene, in combination with pembrolizumab.

CG Oncology announced a 75.2% complete response rate in a key bladder cancer trial and provided a financial update, highlighting a strong cash position following a successful IPO.

CG Oncology's Phase 3 trial of cretostimogene shows a 75.2% complete response rate in patients with high-risk bladder cancer unresponsive to BCG treatment.

CG Oncology disclosed the 2023 bonus awards for its named executive officers, revising the previously reported compensation figures.

CG Oncology successfully closed its initial public offering (IPO) and implemented changes to its certificate of incorporation and bylaws.